Daiichi  Sankyo Co., Ltd. (Tokyo, Japan) will acquire U3 Pharma AG (Martinsried, Germany), a German biotechnology  company focusing on research into antibodies for the treatment of cancer.  Daiichi Sankyo will purchase 100% of the stock and make a one-time payment of  $235 million for the company. 

  U3 Pharma’s  pipeline of novel targeted therapeutics includes programs focusing on fully  human antibodies as potential therapies for breast, lung, and colorectal  cancers, among others. The company’s lead product, which is being co-developed  with Amgen, is U3-1287 (AMG 888), a fully human anti-HER3 monoclonal antibody  to inhibit oncogenic signaling and tumor proliferation. The companies intend to  initiate clinical development of this compound this year.

Mergers and Acquisitions

News

Daiichi Sankyo Co., Ltd. (Tokyo, Japan) will acquire U3 Pharma AG (Martinsried, Germany), a German biotechnology company focusing on research into antibodies for the treatment of cancer.